loading page

Long-term result of 125 I seed brachytherapy for pediatric desmoid tumor in the head and neck
  • +3
  • Yi-Wei Zhong,
  • Xiao-Ming Lyu,
  • Yan Shi,
  • Chuan-Bin Guo,
  • Jian-Guo Zhang,
  • Lei Zheng
Yi-Wei Zhong
Peking University Hospital of Stomatology

Corresponding Author:[email protected]

Author Profile
Xiao-Ming Lyu
Peking University Hospital of Stomatology
Author Profile
Yan Shi
Peking University Hospital of Stomatology
Author Profile
Chuan-Bin Guo
Peking University Hospital of Stomatology
Author Profile
Jian-Guo Zhang
Peking University Hospital of Stomatology
Author Profile
Lei Zheng
Peking University Hospital of Stomatology
Author Profile

Abstract

Background: Desmoid tumor (DT) is rare and challenging, often affects head neck (HN) region in children, and its appropriate treatments are under discussed. This study aimed to retrospectively evaluate long-term effectiveness and safety of 125I seed brachytherapy for pediatric DT in HN. Procedure: Seven pediatric patients with median age of 3 years old suffered from DT in HN treated with 125I brachytherapy from January 2008 to June 2018 were included. Among which, 5 underwent sole brachytherapy and the others combined with surgery under a prescription doses ranging from 10 000 cGy to 12 000 cGy. The rate of local control (LC), complete response (CR) and partial response (PR) were calculated after evaluation by radiological and pathological means. The radiation-associated toxicities were also evaluated Results: The LC rate was 7/7 during the follow-up time ranging from 43 to 135 months and with a mean of 57 months. No recurrent lesion was found in the patients receiving surgery combined with brachytherapy. In patients treated with sole brachytherapy, the radiological PR rate and CR rate were 4/5 and 1/5, respectively. In those reaching radiological PR, 3/4 were pathological CR. Slight acute radiation-associated toxicities were observed in all patients, and no late or severe acute toxicity was observed. Conclusion: 125I brachytherapy is effective and safe in the management of pediatric DT in HN as sole modality or combined with surgery in long term.
13 Jul 2022Submission Checks Completed
13 Jul 2022Assigned to Editor
13 Jul 2022Submitted to Pediatric Blood & Cancer
18 Jul 2022Reviewer(s) Assigned
04 Aug 2022Review(s) Completed, Editorial Evaluation Pending
06 Aug 2022Editorial Decision: Revise Major
13 Aug 2022Submission Checks Completed
13 Aug 2022Assigned to Editor
13 Aug 20221st Revision Received
13 Aug 2022Reviewer(s) Assigned
09 Sep 2022Review(s) Completed, Editorial Evaluation Pending
09 Sep 2022Editorial Decision: Accept
02 Oct 2022Published in Pediatric Blood & Cancer. 10.1002/pbc.30037